JS203, a CD20×CD3 bispecific antibody, demonstrated promising anti-cancer activity in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL): Updated results from a phase I study
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Yan Xie, Hongmei Jing, Yufu Li, Hongming He, Yuerong Shuang, Huangming Hong, Haiyan Yang, Huijing Wu, Liqun Zou, Zengjun Li, Xiaojing Yan, Wei Yang, QI Deng, Hong Cen, Jian Li, Wenyu Li, Zhifang Liu, Hongyan Tong, Li Yu, Yifan Wang, Weiwei Wang, Tong Lu, Shuanghui Wei, Zhihao Jiang, Jianjun Zou, Yuqin Song
Institutions: Peking University Cancer Hospital, Peking University Third Hospital, Henan Cancer Hospital, Fujian Provincial Cancer Hospital, Jiangxi Provincial Cancer Hospital, Sichuan Cancer Hospital, Zhejiang Cancer Hospital, Hubei Cancer Hospital, Sichuan University, West China Hospital of Sichuan University, Shandong First Medical University, First Hospital of China Medical University, China Medical University, Tianjin First Center Hospital, Guangxi Medical University, Tumor Hospital of Guangxi Medical University, Second Affiliated Hospital of Nanchang University, Guangdong Provincial People's Hospital, Second Hospital of Shandong University, First Affiliated Hospital Zhejiang University, Zhejiang University, Junshi Biosciences (China)
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417006000
Cites:
Cited by:
Related to: